Skip to main content
CRS 2025 Annual Meeting & Exposition Main banner

Bioengineering

Tech Session VI: Bioengineering III

Albubody platform for enhanced anti-tumor efficacy of scfv-based drug conjugates

Thursday, July 17, 2025
5:57 PM – 6:08 PM EDT
Introduction: Antibody-drug conjugates (ADCs) are an innovative strategy in targeted cancer therapy, yet single-chain variable fragments (scFvs) face challenges due to their short serum half-life. This study introduces Albubody, a fusion of scFv with an albumin-binding domain (ABD), designed to enhance pharmacokinetics by leveraging serum albumin binding. Using HER2-targeting Albubody as a model, site-specific conjugation of monomethyl auristatin E (MMAE) via strain-promoted azide-alkyne cycloaddition (SPAAC) was employed to create a novel Albubody-drug conjugate.

Learning Objectives:

At the completion of this activity, participants will know
  • Upon completion, participants will be able to compare the pharmacokinetics of scFv and Albubody.
  • Upon completion, participants will be able to understand site-specific drug conjugation.
  • Upon completion, participants will be able to assess Albubody's improved anti-tumor performance.